QA102
Asset
Oral therapy for dry age-related macular degeneration
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Dry age-related macular degeneration
Phase 2, Completed, NCT05536752, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 1 source